Objective: To explore the predictive value of the ratio of monocyte to apolipoprotein A1 (MAR) (a new index related to inflammation and lipid in breast cancer (BC)) and its relationship with clinicopathological staging.
Methods: The hematological test results of 394 patients with breast diseases, including 276 cases of BC, 118 cases of benign breast disease (BBD), and 219 healthy volunteers (HV), were retrospectively collected. The clinical value of MAR was analyzed with binary logistic regression.
Results: Using statistical software analysis, the results showed that MAR level (P< 0.001) was the largest in the BC group, followed by BBD, and the lowest in the HV group, and it was found to be an indicator to distinguish BC from BBD, also an independent risk factor for BC. The increase in MAR level showed that the risk of BC was 3.733 times higher than that of HV (P< 0.001). In addition, there was a notable difference in MAR between early, middle and late stages of BC patients (P=0.047), with the highest MAR level in late stage (0.510± 0.078) and the lowest MAR level in early stage (0.392± 0.011); the MAR level of those with tumor invasion depth of Phase 4 was the highest (0.484± 0.072), and that of Phase 1/2 was the lowest (0.379± 0.010), with a statistically significant difference (P< 0.001). MAR was positively correlated with tumor invasion depth (P< 0.001, r=0.210), that’s, the size of MAR increased when there was more deeper tumor invasion.
Conclusion: MAR is a new indicator for the auxiliary differential diagnosis of benign and malignant breast diseases, and is also an independent risk factor for BC. High-level MAR is closely related to late staging and tumor invasion depth of BC. It can be seen that MAR is a potentially valuable predictor of BC, and this is the first study to explore the clinical value of MAR in BC.
Keywords: breast cancer, breast benign disease, the ratio of monocyte to apolipoprotein A1, Monocyte, Apolipoprotein A1